Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 16, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $101.50 to $30,000,001.88.

Highlighted Stocks Traded by Insiders:

Hilltop Holdings (HTH) - FREE Research Report

Ford Jeremy B, who is President & CEO at Hilltop Holdings, bought 24,938 shares at $20.00 on March 16, 2015. Following this transaction, the President & CEO owned 148,138 shares meaning that the stake was boosted by 20.24% with the 24,938-share transaction.

The shares most recently traded at $19.99, down $0.01, or 0.06% since the insider transaction. Historical insider transactions for Hilltop Holdings go as follows:

  • 4-Week # shares bought: 26,144
  • 4-Week # shares sold: 8,700
  • 12-Week # shares bought: 26,144
  • 12-Week # shares sold: 8,700
  • 24-Week # shares bought: 26,144
  • 24-Week # shares sold: 59,950

The average volume for Hilltop Holdings has been 434,500 shares per day over the past 30 days. Hilltop Holdings has a market cap of $2.0 billion and is part of the financial sector and real estate industry. Shares are up 0.25% year-to-date as of the close of trading on Monday.

Hilltop Holdings Inc. operates as the holding company for PlainsCapital Bank that provides business and consumer banking services in Texas. The company has a P/E ratio of 17.1. Currently, there are 3 analysts who rate Hilltop Holdings a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HTH - FREE

TheStreet Quant Ratings

rates Hilltop Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, growth in earnings per share and attractive valuation levels. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Hilltop Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ANI Pharmaceuticals (ANIP) - FREE Research Report

Meridian Venture Partners Ii Lp, who is 10% Owner at ANI Pharmaceuticals, sold 300,000 shares at $63.00 on March 16, 2015. Following this transaction, the 10% Owner owned 2.4 million shares meaning that the stake was reduced by 11.32% with the 300,000-share transaction.

Przybyl Arthur, who is President and CEO at ANI Pharmaceuticals, sold 75,000 shares at $63.00 on March 16, 2015. Following this transaction, the President and CEO owned 114,164 shares meaning that the stake was reduced by 39.65% with the 75,000-share transaction.

Arnold Charlotte C., who is Vice President and CFO at ANI Pharmaceuticals, sold 45,000 shares at $63.00 on March 16, 2015. Following this transaction, the Vice President and CFO owned 21,385 shares meaning that the stake was reduced by 67.79% with the 45,000-share transaction.

The shares most recently traded at $61.65, down $1.35, or 2.19% since the insider transaction. Historical insider transactions for ANI Pharmaceuticals go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 5,000

The average volume for ANI Pharmaceuticals has been 335,500 shares per day over the past 30 days. ANI Pharmaceuticals has a market cap of $687.0 million and is part of the health care sector and drugs industry. Shares are up 11.63% year-to-date as of the close of trading on Monday.

ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals. It manufactures oral solid dose products, as well as liquids and topicals, narcotics, and potent products. The company has a P/E ratio of 23.3. Currently, there are 2 analysts who rate ANI Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANIP - FREE

TheStreet Quant Ratings

rates ANI Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full

ANI Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Salesforce.com (CRM) - FREE Research Report

Benioff Marc, who is Chairman of the Board & CEO at Salesforce.com, sold 25,000 shares at $65.25 on March 16, 2015. Following this transaction, the Chairman of the Board & CEO owned 38.1 million shares meaning that the stake was reduced by 0.07% with the 25,000-share transaction.

Conway Craig, who is Director at Salesforce.com, sold 2,227 shares at $65.28 on March 16, 2015. Following this transaction, the Director owned 9,416 shares meaning that the stake was reduced by 19.13% with the 2,227-share transaction.

The shares most recently traded at $66.51, up $1.23, or 1.85% since the insider transaction. Historical insider transactions for Salesforce.com go as follows:

  • 4-Week # shares sold: 232,900
  • 12-Week # shares sold: 652,400
  • 24-Week # shares sold: 1.5 million

The average volume for Salesforce.com has been 4.7 million shares per day over the past 30 days. Salesforce.com has a market cap of $42.0 billion and is part of the technology sector and computer software & services industry. Shares are up 12% year-to-date as of the close of trading on Monday.

salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship management to various businesses and industries worldwide. Currently, there are 24 analysts who rate Salesforce.com a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRM - FREE

TheStreet Quant Ratings

rates Salesforce.com as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full

Salesforce.com Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null